CStone Pharmaceuticals (CSPHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CStone Pharmaceuticals (CSPHF) with AI Score 50/100 (Hold). CStone Pharmaceuticals is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026CStone Pharmaceuticals (CSPHF) Healthcare & Pipeline Overview
CStone Pharmaceuticals is a biopharmaceutical company focused on immuno-oncology and precision medicines for cancer patients in China and internationally. With a pipeline of novel therapies and strategic collaborations, CStone aims to address unmet medical needs, although it currently operates with negative profit margins in a competitive market.
Investment Thesis
CStone Pharmaceuticals presents a compelling, albeit high-risk, investment thesis centered on its innovative pipeline of immuno-oncology and precision medicine assets. The company's focus on addressing unmet medical needs in the oncology space, particularly in China, offers significant growth potential. Key value drivers include the successful commercialization of Sugemalimab and GAVRETO, as well as the advancement of its pipeline assets like Nofazinlimab and Fisogatinib. The company's current market capitalization of $1.26 billion reflects investor expectations for future growth, but its negative profit margin of -136.1% underscores the challenges it faces in achieving profitability. Upcoming clinical trial results and regulatory approvals will serve as key catalysts. However, potential risks include competition from established pharmaceutical companies and the inherent uncertainties in drug development.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.26 billion indicates investor confidence in CStone's pipeline and future growth potential.
- Negative P/E ratio of -33.21 reflects the company's current lack of profitability due to ongoing R&D investments.
- Gross Margin of 12.2% indicates the profitability of CStone's current product sales after accounting for the cost of goods sold.
- Beta of 0.61 suggests that the stock is less volatile than the overall market.
- The company's focus on immuno-oncology and precision medicines positions it in a high-growth area of the pharmaceutical industry.
Competitors & Peers
Strengths
- Innovative drug pipeline targeting unmet medical needs in oncology.
- Strategic focus on the Chinese market with significant growth potential.
- Established partnerships with leading pharmaceutical companies.
- Experienced management team with expertise in drug development and commercialization.
Weaknesses
- Negative profit margin and reliance on external funding.
- Limited commercial track record compared to established pharmaceutical companies.
- High R&D expenses and long drug development timelines.
- Dependence on regulatory approvals for drug commercialization.
Catalysts
- Upcoming: Clinical trial results for Nofazinlimab in hepatocellular carcinoma expected in 2026.
- Upcoming: Potential regulatory approval for Sugemalimab in additional cancer indications by 2027.
- Ongoing: Expansion of commercial operations in China and international markets.
- Ongoing: Strategic partnerships and licensing agreements to expand the drug pipeline.
- Ongoing: Development and advancement of novel immuno-oncology and precision medicine assets.
Risks
- Potential: Competition from established pharmaceutical companies with larger resources.
- Potential: Uncertainties in clinical trial outcomes and regulatory approvals.
- Ongoing: Pricing pressures and reimbursement challenges in the Chinese market.
- Potential: Intellectual property disputes and patent expirations.
- Ongoing: Negative profit margin and reliance on external funding.
Growth Opportunities
- Expansion of Sugemalimab's Indications: Sugemalimab, CStone's anti-PD-L1 antibody, has the potential for expanded use across multiple cancer types. Securing regulatory approvals for additional indications, such as non-small cell lung cancer and gastric cancer, could significantly increase its market reach. The global market for PD-L1 inhibitors is substantial, offering a considerable revenue opportunity for CStone. Timeline: Ongoing clinical trials and regulatory submissions expected through 2027.
- Advancement of Nofazinlimab for Hepatocellular Carcinoma: Nofazinlimab, a PD-1 antibody, targets hepatocellular carcinoma (HCC), a prevalent cancer in China and globally. Positive clinical trial results and subsequent regulatory approval could establish Nofazinlimab as a key treatment option for HCC patients. The HCC market is expected to grow, driven by increasing incidence and limited treatment options. Timeline: Clinical trial data expected in 2026, with potential regulatory submission in 2027.
- Commercialization of Fisogatinib for FGFR4-Driven Cancers: Fisogatinib, an FGFR4 inhibitor, targets cancers driven by FGFR4 mutations, including hepatocellular carcinoma. Successful clinical development and commercialization could provide a targeted therapy for a specific subset of cancer patients. The market for FGFR inhibitors is emerging, offering a first-in-class opportunity for CStone. Timeline: Ongoing clinical trials with potential for accelerated approval pathways.
- Strategic Partnerships and Licensing Agreements: CStone can leverage strategic partnerships and licensing agreements to expand its pipeline and geographic reach. Collaborating with other pharmaceutical companies or research institutions can accelerate drug development and commercialization efforts. Licensing agreements can provide access to novel technologies and therapies. Timeline: Ongoing business development activities with potential for near-term announcements.
- Expansion into New Geographic Markets: While CStone is primarily focused on the Chinese market, expanding into other geographic regions, such as Southeast Asia or Europe, could drive future growth. Securing regulatory approvals and establishing commercial operations in new markets would require significant investment but could unlock substantial revenue opportunities. Timeline: Long-term strategic goal with potential for initial expansion efforts in 2028-2030.
Opportunities
- Expansion of existing drug indications to increase market reach.
- Advancement of pipeline assets to address additional cancer types.
- Strategic partnerships and licensing agreements to expand pipeline and geographic reach.
- Entry into new geographic markets beyond China.
Threats
- Competition from established pharmaceutical companies with larger resources.
- Uncertainties in clinical trial outcomes and regulatory approvals.
- Pricing pressures and reimbursement challenges in the Chinese market.
- Intellectual property disputes and patent expirations.
Competitive Advantages
- Proprietary drug pipeline with novel immuno-oncology and precision medicine assets.
- Strong research and development capabilities.
- Strategic partnerships with leading pharmaceutical companies.
- Established presence in the Chinese oncology market.
- Intellectual property protection for key drug candidates.
About CSPHF
CStone Pharmaceuticals, established in 2015 and headquartered in Shanghai, China, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology and precision medicines. The company's mission is to address the unmet medical needs of cancer patients both in China and globally. CStone's portfolio includes Sugemalimab, a monoclonal antibody against programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor used in the treatment of advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor targeted at adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. Beyond its currently marketed products, CStone Pharmaceuticals has a robust pipeline of drug candidates, including Nofazinlimab, a PD-1 antibody for hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor for relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor for hepatocellular carcinoma. The company is also developing several other compounds, such as CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors, as well as CS5001 for both solid tumors and hematologic malignancies. CStone operates in a highly competitive biotechnology landscape, focusing on innovative therapies for cancer treatment.
What They Do
- Researches and develops immuno-oncology drugs.
- Develops precision medicines for cancer treatment.
- Commercializes oncology drugs in China and internationally.
- Focuses on addressing unmet medical needs in cancer care.
- Offers Sugemalimab, a PD-L1 antibody.
- Provides GAVRETO, an RET inhibitor for thyroid cancers.
- Develops avapritinib, a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors.
Business Model
- Develops and patents novel oncology drugs.
- Conducts clinical trials to demonstrate drug efficacy and safety.
- Obtains regulatory approvals for drug commercialization.
- Manufactures and markets approved drugs.
- Generates revenue through drug sales.
Industry Context
CStone Pharmaceuticals operates within the rapidly evolving biotechnology industry, specifically targeting the oncology market. The global oncology market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and increasing cancer incidence. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, such as ASCLF (Ascentage Pharma), CHIZF (Chi-Med), CSBTF (Connect Biopharma), MEOBF (Meihua International Medical Technologies), and NURPF (Nurexone Biologic). CStone differentiates itself through its focus on innovative therapies and its strategic presence in the Chinese market.
Key Customers
- Cancer patients in China and internationally.
- Hospitals and oncology clinics.
- Healthcare providers prescribing cancer treatments.
- Government healthcare systems.
- Private insurance companies.
Financials
Chart & Info
CStone Pharmaceuticals (CSPHF) stock price: Price data unavailable
Latest News
No recent news available for CSPHF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSPHF.
Price Targets
Wall Street price target analysis for CSPHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CSPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jianxin Yang
CEO
Jianxin Yang serves as the CEO of CStone Pharmaceuticals, leading a team of 135 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at several multinational pharmaceutical companies, where he oversaw the development and launch of multiple oncology drugs. Yang's expertise spans clinical research, regulatory affairs, and market access.
Track Record: Under Jianxin Yang's leadership, CStone Pharmaceuticals has advanced its pipeline of immuno-oncology and precision medicine assets, securing regulatory approvals for key drugs like Sugemalimab and GAVRETO. He has also overseen strategic partnerships and licensing agreements to expand the company's portfolio. Yang's focus on innovation and commercial execution has driven CStone's growth in the competitive oncology market.
CSPHF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that CStone Pharmaceuticals (CSPHF) may not meet the minimum financial or disclosure requirements for higher OTC tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for price volatility and manipulation.
- Increased risk of fraud or misrepresentation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and regulatory filings.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established partnerships with reputable pharmaceutical companies.
- Progress in clinical trials and regulatory approvals for key drugs.
- Experienced management team with expertise in the pharmaceutical industry.
- Focus on addressing unmet medical needs in oncology.
- Presence in the Chinese market with significant growth potential.
Common Questions About CSPHF
What does CStone Pharmaceuticals do?
CStone Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative immuno-oncology and precision medicines. The company aims to address unmet medical needs for cancer patients in China and internationally. Its portfolio includes drugs like Sugemalimab and GAVRETO, and it has a robust pipeline of drug candidates targeting various cancer types. CStone operates by developing and patenting novel oncology drugs, conducting clinical trials, obtaining regulatory approvals, and manufacturing and marketing approved drugs.
What do analysts say about CSPHF stock?
Analyst coverage of CSPHF stock is limited due to its OTC listing and smaller market capitalization. However, the general sentiment is cautiously optimistic, reflecting the potential of its drug pipeline and strategic focus on the Chinese market. Key valuation metrics include its market capitalization of $1.26 billion and negative P/E ratio of -33.21, reflecting its current lack of profitability. Growth considerations include the successful commercialization of its existing drugs and the advancement of its pipeline assets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for CSPHF?
The main risks for CStone Pharmaceuticals include competition from established pharmaceutical companies, uncertainties in clinical trial outcomes and regulatory approvals, pricing pressures and reimbursement challenges in the Chinese market, intellectual property disputes, and its negative profit margin. As an OTC-listed company, CSPHF also faces risks related to limited financial disclosure, lower trading volume, and potential price volatility. These factors could impact the company's ability to achieve its growth objectives and generate returns for investors. Investors should carefully consider these risks before investing in CSPHF.
What are the key factors to evaluate for CSPHF?
CStone Pharmaceuticals (CSPHF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Innovative drug pipeline targeting unmet medical needs in oncology.. Primary risk to monitor: Potential: Competition from established pharmaceutical companies with larger resources.. This is not financial advice.
How frequently does CSPHF data refresh on this page?
CSPHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CSPHF's recent stock price performance?
Recent price movement in CStone Pharmaceuticals (CSPHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative drug pipeline targeting unmet medical needs in oncology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CSPHF overvalued or undervalued right now?
Determining whether CStone Pharmaceuticals (CSPHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CSPHF?
Before investing in CStone Pharmaceuticals (CSPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided data and may be subject to change.
- OTC market data may have limited availability and accuracy.